Cited by 218Fatty Acid Research and HealthAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease

Open access

Astarita, Giuseppe, Jung, Kwang-Mook, Berchtold, Nicole C., Nguyen, Vinh Q., Gillen, Daniel L., Head, Elizabeth, Cotman, Carl W., Piomelli, Daniele·2010·PLoS ONE

DOI 10.1371/journal.pone.0012538PMC PMC2935886

Open this paper in CoChat — free account

Abstract

Reduced brain levels of docosahexaenoic acid (C22:6n-3), a neurotrophic and neuroprotective fatty acid, may contribute to cognitive decline in Alzheimer's disease. Here, we investigated whether the liver enzyme system that provides docosahexaenoic acid to the brain is dysfunctional in this disease. Docosahexaenoic acid levels were reduced in temporal cortex, mid-frontal cortex and cerebellum of subjects with Alzheimer's disease, compared to control subjects (P = 0.007). Mini Mental State Examination (MMSE) scores positively correlated with docosahexaenoic/α-linolenic ratios in temporal cortex (P = 0.005) and mid-frontal cortex (P = 0.018), but not cerebellum. Similarly, liver docosahexaenoic acid content was lower in Alzheimer's disease patients than control subjects (P = 0.011). Liver docosahexaenoic/α-linolenic ratios correlated positively with MMSE scores (r = 0.78; P<0.0001), and negatively with global deterioration scale grades (P = 0.013). Docosahexaenoic acid precursors, including tetracosahexaenoic acid (C24:6n-3), were elevated in liver of Alzheimer's disease patients (P = 0.041), whereas expression of peroxisomal d-bifunctional protein, which catalyzes the conversion of tetracosahexaenoic acid into docosahexaenoic acid, was reduced (P = 0.048). Other genes involved in docosahexaenoic acid metabolism were not affected. The results indicate that a deficit in d-bifunctional protein activity impairs docosahexaenoic acid biosynthesis in liver of Alzheimer's disease patients, lessening the flux of this neuroprotective fatty acid to the brain.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0012538

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Overview of docosahexaenoic acid biosynthesis in liver. Diet-derived α-linolenic acid (C18:3n-3) is transformed into tetracosahexaenoic acid (C24:6n-3) by the sequential action of Δ6 and Δ5 desaturases (encoded by the FADS2 and FADS1 genes, respectively) and elongases (such as that encoded by the HELO1 gene) present in the endoplasmatic reticulum. Tetracosahexaenoic acid is transported into peroxisomes (shaded area), presumably by proteins encoded by the ABCD1 or ABCD2 genes, and then converted into docosahexaenoic acid (C22:6n-3) by sequential action of acyl coenzyme-A oxidase (encoded by the ACOX1 gene), d-bifunctional protein (encoded by the HSD17B4 gene), and various peroxisomal thiolases (not shown). The figure shows chemical structures of fatty acids quantified in our analyses.CC BY · PubMed Central

Figure 2 Liver metabolism in Alzheimer's disease patients. Levels of free docosahexaenoic acid (Panel A) and 1-O-1′-(Z)-octadecenyl, 2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (Panel B) in liver tissue from control subjects (open squares) and Alzheimer's disease patients (closed circles). Correlation between individual docosahexaenoic/α-linolenic ratios in liver and most recent Mini-Mental State Examination scores (Panel C) or global deterioration scale grades (Panel D). HSD17B4 mRNA, encoding for d-bifunctional protein (Panel E) and pristanic acid levels (Panel F) in liver from control subjects (open squares) and subjects with Alzheimer's disease (closed circles). Lipid content is expressed in nanomoles per gram of wet tissue and mRNA levels are expressed in arbitrary units. There were statistically detectable differences between control subjects and Alzheimer's disease patients in the levels of docosahexaenoic acid (P = 0.0077) and 1-O-1′-(Z)-octadecenyl, 2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (P = 0.003) by two-tailed Welch's t-test. There was a significant correlation between docosahexaenoic/α-linolenic ratios in liver and Mini-Mental State Examination scores with use of the partial correlation analysis after adjustment for age, gender and post mortem interval. Global deterioration scale grades correlate significantly (P = 0.013) with the docosahexaenoic/α-linolenic ratios using a linear regression analysis adjusting for age, gender and post mortem interval. There were statistically detectable differences between control subjects and patients in the levels of HSD17B4 mRNA (P = 0.048) and pristanic acid (P = 0.0009) by two-tailed Welch's t-test.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity
White, H. (1980) · Econometrica · doi:10.2307/1912934 · Cited by 25,861
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Origins and evolution of the Western diet: health implications for the 21st century1,2
Cordain, L., Eaton, S. B., Sebastian, A., Mann, N., Lindeberg, S., Watkins, B. A., O’Keefe, J. H., & Brand-Miller, J. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn.81.2.341 · Cited by 2,397
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Alzheimer’s disease
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Conversion of α -linolenic acid to longer-chain polyunsaturated fatty acids in human adults
Burdge, G. C., & Calder, P. C. (2005) · Reproduction Nutrition Development · doi:10.1051/rnd:2005047 · Cited by 939
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease
Lukiw, W. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25420 · Cited by 897
Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress
Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., & Bazan, N. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402531101 · Cited by 753 · cited 1×
“The polyunsaturated lipid, docosahexaenoic acid (C22:6n-3), is an essential component of neuronal membranes [4,5] and a precursor for potent neuroprotective mediators [6–8].”
Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model
Calon, F., Lim, G. P., Yang, F., Morihara, T., Teter, B., Ubeda, O., Rostaing, P., Triller, A., Salem, N., Ashe, K. H., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.013 · Cited by 707
Dietary omega 3 fatty acids and the developing brain
Innis, S. M. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.078 · Cited by 699

Show all 42 references

Sorted by citations

Functions of plasmalogen lipids in health and disease
Braverman, N. E., & Moser, A. B. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.05.008 · Cited by 1,082
Long-chain omega-3 fatty acids and the brain: A review of the independent and shared effects of EPA, DPA and DHA
Dyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
DHA Effects in Brain Development and Function
Lauritzen, L., Brambilla, P., Mazzocchi, A., Harsløf, L. B. S., Ciappolino, V., & Agostoni, C. V. (2016) · Nutrients · doi:10.3390/nu8010006 · Cited by 566
Significance of long chain polyunsaturated fatty acids in human health
Zárate, R., el Jaber-Vazdekis, N., Tejera, N., Pérez, J. A., & Rodríguez, C. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0153-6 · Cited by 573
Homocysteine, B Vitamins, and Cognitive Impairment
Smith, A. D., & Refsum, H. (2016) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071715-050947 · Cited by 526
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460
Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer’s, and other neurodegenerative diseases
Bazan, N. G., Molina, M. F., & Gordon, W. C. (2011) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104635 · Cited by 441
Docosahexaenoic Acid and Cognition throughout the Lifespan
Weiser, M., Butt, C., & Mohajeri, M. (2016) · Nutrients · doi:10.3390/nu8020099 · Cited by 400
Plasma nutrient status of patients with Alzheimer's disease: Systematic review and meta‐analysis
da Silva, S. L., Vellas, B. J., Elemans, S., Luchsinger, J. A., Kamphuis, P. J. G. H., Yaffe, K. S., Sijben, J., Groenendijk, M., & Stijnen, T. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1771 · Cited by 313
A systematic integrated analysis of brain expression profiles reveals YAP1 and other prioritized hub genes as important upstream regulators in Alzheimer's disease
Xu, M., Zhang, D., Luo, R., Wu, Y., Zhou, H., Kong, L., Bi, R., & Yao, Y. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.08.012 · Cited by 296
Mitochondria-associated ER membranes in Alzheimer disease
Schon, E. A., & Area-Gomez, E. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.07.011 · Cited by 261
Docosahexaenoic Acid-Derived Neuroprotectin D1 Induces Neuronal Survival via Secretase- and PPARγ-Mediated Mechanisms in Alzheimer's Disease Models
Zhao, Y., Calon, F., Julien, C., Winkler, J. W., Petasis, N. A., Lukiw, W. J., & Bazan, N. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015816 · Cited by 243
ER stress and impaired autophagy flux in neuronal degeneration and brain injury
Yin, Y., Sun, G., Li, E., Kiselyov, K. I., & Sun, D. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.08.008 · Cited by 218
Brain docosahexaenoic acid uptake and metabolism
Lacombe, R. J. S., Chouinard‐Watkins, R., & Bazinet, R. P. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.12.004 · Cited by 225
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target
Li, R.-Y., Qin, Q., Yang, H.-C., Wang, Y.-Y., Mi, Y.-X., Yin, Y.-S., Wang, M., Yu, C.-J., & Tang, Y. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00542-y · Cited by 204
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9544-0 · Cited by 204
Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease
González‐Domínguez, R., García‐Barrera, T., & Gómez‐Ariza, J. L. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.10.010 · Cited by 205
Lipidomics of Human Brain Aging and Alzheimer's Disease Pathology
Naudí, A., Cabré, R., Jové, M., Ayala, V., Gonzalo‐Benito, H., Portero‐Otín, M., Ferrer, I., & Pamplona, R. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.008 · Cited by 214
Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration
Rojas-Gutierrez, E., Muñoz‐Arenas, G., Treviño, S., Espinosa, B., Chávez, R., Rojas, K., Flores, G., Díaz, A., & Guevara, J. (2017) · Synapse · doi:10.1002/syn.21990 · Cited by 205
Peroxisomes in brain development and function
Berger, J., Dorninger, F., Forss-Petter, S., & Kunze, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.12.005 · Cited by 194
“Also, a decrease inDHA,whose endogenous de novo production requires peroxisomes, in brain and liver [276] and a regional decrease in catalase activity in the temporal lobe [277] were reported.”
Background
Plasmalogens and Alzheimer’s disease: A review
Su, X. Q., Wang, J., & Sinclair, A. J. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1044-1 · Cited by 172
Lipidomics of Alzheimer's disease: current status
Wood, P. L. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt103 · Cited by 167
Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease
Astarita, G., Jung, K.-M., Vasilevko, V., DiPatrizio, N. V., Martin, S. K., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024777 · Cited by 146
Self-citation
Neuroglialpharmacology: Myelination as a shared mechanism of action of psychotropic treatments
Bartzokis, G. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.015 · Cited by 142
Lower brain and blood nutrient status in Alzheimer's disease: Results from meta‐analyses
de Wilde, M. C., Vellas, B. J., Girault, E. M., Cetinyurek‐Yavuz, A., & Sijben, J. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.06.002 · Cited by 144
Unbiased Metabolomic Investigation of Alzheimer’s Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism
Paglia, G., Stocchero, M., Cacciatore, S., Lai, S., Angel, P. M., Alam, M. T., Keller, M. A., Ralser, M., & Astarita, G. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01020 · Cited by 136
Self-citation
Peroxisome quality control and dysregulated lipid metabolism in neurodegenerative diseases
Jo, D. S., Park, N. Y., & Cho, D. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00503-9 · Cited by 143
An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease
Jung, K., Astarita, G., Yaşar, S., Vasilevko, V., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.012 · Cited by 136
Self-citation
Targeting Synaptic Dysfunction in Alzheimer’s Disease by Administering a Specific Nutrient Combination
van Wijk, N., Broersen, L. M., de Wilde, M. C., Hageman, R. J. J., Groenendijk, M., Sijben, J. W. C., & Kamphuis, P. J. G. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130998 · Cited by 128
Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer’s disease
Heras-Sandoval, D., Pedraza‐Chaverrí, J., & Pérez‐Rojas, J. M. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0525-7 · Cited by 126
A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease
Olazarán, J., Gil‐de‐Gómez, L., Rodríguez‐Martín, A., Valentí, M., Payo, B. F., Marín-Muñoz, J., Antúnez, C., Frank, A., Acedo, C., Gracia, L. M., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142925 · Cited by 120
Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention
Grimm, M. O. W., Michaelson, D. M., & Hartmann, T. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076331 · Cited by 114
An Emerging Role for Metabolomics in Nutrition Science
Astarita, G., & Langridge, J. (2013) · Lifestyle Genomics · doi:10.1159/000354403 · Cited by 110
Self-citation
Effect of dietary docosahexaenoic acid (DHA) in phospholipids or triglycerides on brain DHA uptake and accretion
Kitson, A. P., Metherel, A. H., Chen, C. T., Domenichiello, A. F., Trépanier, M., Berger, A., & Bazinet, R. P. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.02.009 · Cited by 112
Brain peroxisomes
Trompier, D., Véjux, A., Zarrouk, A., Gondcaille, C., Geillon, F., Nury, T., Savary, S., & Lizard, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.09.009 · Cited by 106
Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions
Ren, F., Wei, J., Chen, Q., Hu, M., Yu, L., Mi, J., Zhou, X., Qin, D., Wu, J., & Wu, A. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.030 · Cited by 97
Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection
Asatryan, A., & Bazan, N. G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.783076 · Cited by 99
Mass Spectrometry Strategies for Clinical Metabolomics and Lipidomics in Psychiatry, Neurology, and Neuro-Oncology
Wood, P. L. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.167 · Cited by 95
Dietary Docosahexaenoic Acid Supplementation in Children With Autism
Voigt, R. G., Mellon, M. W., Katusic, S. K., Weaver, A. L., Matern, D., Mellon, B., Jensen, C. L., & Barbaresi, W. J. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000260 · Cited by 94
Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?
Cunnane, S. C., Chouinard‐Watkins, R., Castellano, C., & Barberger‐Gateau, P. (2012) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2012.04.006 · Cited by 99
Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders
Wu, A., Noble, E. E., Tyagi, E., Ying, Z., Zhuang, Y., & Gómez‐Pinilla, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.005 · Cited by 92
Nutritional approaches in the risk reduction and management of Alzheimer's disease
Mi, W., van Wijk, N., Cansev, M., Sijben, J., & Kamphuis, P. J. G. H. (2013) · Nutrition · doi:10.1016/j.nut.2013.01.024 · Cited by 91
Differences in Nutritional Status Between Very Mild Alzheimer's Disease Patients and Healthy Controls
Rikkert, M. G. M. O., Verhey, F. R. J., Sijben, J., Bouwman, F. H., DAUTZENBERG, P. L. J., Lansink, M., Sipers, W. M. W. H., van Asselt, D. Z. B., van Hees, A. M. J., Stevens, M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131892 · Cited by 88
Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease
Bennett, S. A. L., Valenzuela, N., Xu, H., Franko, B., Fai, S., & Figeys, D. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00168 · Cited by 89
Alzheimer’s Disease: Pathogenesis and Therapeutic Interventions
Ogbodo, J. O., Agbo, C. P., Njoku, U. O., Ogugofor, M. O., Egba, S. I., Ihim, S. A., Echezona, A. C., Brendan, K. C., Upaganlawar, A. B., & Upasani, C. D. (2021) · Current Aging Science · doi:10.2174/1874609814666210302085232 · Cited by 86
Identification of age- and gender-associated long noncoding RNAs in the human brain with Alzheimer's disease
Cao, M., Li, H., Zhao, J., Cui, J., & Hu, G. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.023 · Cited by 81
Alteration of Metabolic Profile and Potential Biomarkers in the Plasma of Alzheimer’s Disease
Shao, Y., Ouyang, Y., Li, T., Liu, X., Xu, X., Li, S., Xu, G., & Le, W. (2020) · Aging and Disease · doi:10.14336/ad.2020.0217 · Cited by 79
The blood‐brain barrier fatty acid transport protein 1 ( FATP 1/ SLC 27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport
Ochiai, Y., Uchida, Y., Ohtsuki, S., Tachikawa, M., Aizawa, S., & Terasaki, T. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13943 · Cited by 74
Age-related changes in brain phospholipids and bioactive lipids in the APP knock-in mouse model of Alzheimer’s disease
Emre, C., Do, K. V., Jun, B., Hjorth, E., Alcalde, S. G., Kautzmann, M.-A. I., Gordon, W. C., Nilsson, P., Bazan, N. G., & Schultzberg, M. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01216-4 · Cited by 75
Roles of the Unsaturated Fatty Acid Docosahexaenoic Acid in the Central Nervous System: Molecular and Cellular Insights
Toledo, A. P., Reyna‐Jeldes, M., Ortega, L., Coddou, C., & Yévenes, G. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105390 · Cited by 74
DHA-PC and DHA-PS improved Aβ1–40 induced cognitive deficiency uncoupled with an increase in brain DHA in rats
Wen, M., Ding, L., Zhang, L., Zhou, M., Xu, J., Wang, J., Wang, Y., & Xue, C. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.02.004 · Cited by 71
Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids
Torres, M., Parets, S., Fernández-Díaz, J., Beteta-Göbel, R., Rodríguez-Lorca, R., Román, R., Lladó, V., Rosselló, C. A., Fernández‐García, P., & Escribá, P. V. (2021) · Membranes · doi:10.3390/membranes11120919 · Cited by 80
Exercise facilitates the action of dietary DHA on functional recovery after brain trauma
Wu, A. D., Ying, Z., & Gómez‐Pinilla, F. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.06.041 · Cited by 72
Relationship between central and peripheral fatty acids in humans
Guest, J., Garg, M. L., BILGIN, A. A. B., & Grant, R. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-79 · Cited by 69
Lipidomics applications in health, disease and nutrition research
MURPHY, S. A., & Nicolaou, A. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200863 · Cited by 74
New Perspectives on Alzheimer’s Disease and Nutrition
Gustafson, D., Morris, M. C., Scarmeas, N., Shah, R. C., Sijben, J., Yaffe, K. S., & Zhu, X. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150084 · Cited by 71
A nutrient combination that can affect synapse formation
Wurtman, R. (2014) · Nutrients · doi:10.3390/nu6041701 · Cited by 68
Lipidomics of Bioactive Lipids in Alzheimer’s and Parkinson’s Diseases: Where Are We?
Chiurchiù, V., Tiberi, M., Matteocci, A., Fazio, F., Siffeti, H., Saracini, S., Mercuri, N. B., & Sancesario, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116235 · Cited by 73
Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer's disease
Torres, M., Price, S. L., Fiol-deRoque, M. A., Marcilla-Etxenike, A., Ahyayauch, H., Barceló‐Coblijn, G., Terés, S., Katsouri, L., Ordinas, M., López, D. J., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.12.016 · Cited by 68
Fatty Acid Metabolism in Carriers of Apolipoprotein E Epsilon 4 Allele: Is It Contributing to Higher Risk of Cognitive Decline and Coronary Heart Disease?
Chouinard‐Watkins, R., & Plourde, M. (2014) · Nutrients · doi:10.3390/nu6104452 · Cited by 73
Peroxisomal Stress Response and Inter-Organelle Communication in Cellular Homeostasis and Aging
Kim, J., & Bai, H. (2022) · Antioxidants · doi:10.3390/antiox11020192 · Cited by 64
Peroxisomal dysfunction in neurodegenerative diseases
Jo, D. S., & Cho, D. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01131-2 · Cited by 66
Targeted Metabolomic Analysis in Alzheimer’s Disease Plasma and Brain Tissue in Non-Hispanic Whites
Kalecký, K., German, D. C., Montillo, A., & Bottiglieri, T. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215448 · Cited by 65
Brain targeting with docosahexaenoic acid as a prospective therapy for neurodegenerative diseases and its passage across blood brain barrier
Hachem, M., Belkouch, M., Van, A. L., Picq, M., Bernoud‐Hubac, N., & Lagarde, M. (2020) · Biochimie · doi:10.1016/j.biochi.2020.01.013 · Cited by 61
Potential Links between Impaired One-Carbon Metabolism Due to Polymorphisms, Inadequate B-Vitamin Status, and the Development of Alzheimer’s Disease
Troesch, B., Weber, P., & Mohajeri, M. H. (2016) · Nutrients · doi:10.3390/nu8120803 · Cited by 63
Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)
Wood, P. L., Locke, V. A., Herling, P., Passaro, A., Vigna, G. B., Volpato, S., Valacchi, G., Cervellati, C., & Zuliani, G. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.11.004 · Cited by 61
Alterations in the Levels of Amyloid-β, Phospholipid Hydroperoxide, and Plasmalogen in the Blood of Patients with Alzheimer’s Disease: Possible Interactions between Amyloid-β and These Lipids
Yamashita, S., Kiko, T., Fujiwara, H., Hashimoto, M., Nakagawa, K., Kinoshita, M., Furukawa, K., Arai, H., & Miyazawa, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150640 · Cited by 60
Mechanisms of DHA-enriched phospholipids in improving cognitive deficits in aged SAMP8 mice with high-fat diet
Zhou, M., Ding, L., Wen, M., Che, H., Huang, J., Zhang, T., Xue, C., Mao, X., & Wang, Y.-M. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.05.009 · Cited by 60
Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer’s Disease from Controls and Predict Progression from Mild Cognitive Impairment
Llano, D. A., Initiative, A. D. N., & Devanarayan, V. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201420 · Cited by 58
Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer’s disease
Sanfilippo, C., Castrogiovanni, P., Imbesi, R., Kazakowa, M., Musumeci, G., Blennow, K., Zetterberg, H., & Rosa, M. D. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146305 · Cited by 57
Fatty Acids: From Membrane Ingredients to Signaling Molecules
Hashimoto, M., & Hossain, S. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.80430 · Cited by 51
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
The docosanoid neuroprotectin D1 induces homeostatic regulation of neuroinflammation and cell survival
Bazan, N. G. (2012) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2012.08.008 · Cited by 54
Neuroprotectin D1 Induces Neuronal Survival and Downregulation of Amyloidogenic Processing in Alzheimer’s Disease Cellular Models
Stark, D. T., & Bazan, N. G. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8174-4 · Cited by 49
The omega-3 hydroxy fatty acid 7( S )-HDHA is a high-affinity PPARα ligand that regulates brain neuronal morphology
Liu, J., Sahin, C., Ahmad, S., Magomedova, L., Zhang, M., Jia, Z., Metherel, A. H., Orellana, A. J., Poda, G. I., Bazinet, R. P., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abo1857 · Cited by 48
Non-Alcoholic Fatty Liver Disease, and the Underlying Altered Fatty Acid Metabolism, Reveals Brain Hypoperfusion and Contributes to the Cognitive Decline in APP/PS1 Mice
Pinçon, A., de Montgolfier, O., Akkoyunlu, N., Daneault, C., Pouliot, P., Villeneuve, L. R., Lesage, F., Levy, B. I., Thorin‐Trescases, N., Thorin, É., et al. (2019) · Metabolites · doi:10.3390/metabo9050104 · Cited by 47
Meta-Analysis of Gene Expression Changes in the Blood of Patients with Mild Cognitive Impairment and Alzheimer’s Disease Dementia
Bottero, V., & Potashkin, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215403 · Cited by 47
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
Rijpma, A., Meulenbroek, O., van Hees, A. M. J., Sijben, J., Vellas, B. J., Shah, R. C., Bennett, D. A., Scheltens, P., & Rikkert, M. G. M. O. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0134-1 · Cited by 44
Towards a whole-body systems [multi-organ] lipidomics in Alzheimer’s disease
Astarita, G., & Piomelli, D. (2011) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2011.04.021 · Cited by 45
Self-citation
Fatty acids and beyond: Age and Alzheimer's disease related changes in lipids reveal the neuro-nutraceutical potential of lipids in cognition
Ooi, K.-L. M., Vacy, K., & Boon, W. C. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105143 · Cited by 42
Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline
Hennebelle, M., Plourde, M., Chouinard‐Watkins, R., Castellano, C., Barberger‐Gateau, P., & Cunnane, S. C. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003625 · Cited by 42
Chronic inflammation, neuroglial dysfunction, and plasmalogen deficiency as a new pathobiological hypothesis addressing the overlap between post-COVID-19 symptoms and myalgic encephalomyelitis/chronic fatigue syndrome
Filho, A. J. M. C., Braniff, O., Angelova, A., Deng, Y., & Tremblay, M. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110702 · Cited by 41
The phospholipid composition of the human entorhinal cortex remains relatively stable over 80 years of adult aging
Hancock, S. E., Friedrich, M. G., Mitchell, T. W., Truscott, R. J. W., & Else, P. L. (2017) · GeroScience · doi:10.1007/s11357-017-9961-2 · Cited by 41
Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease
Wood, P. L., Smith, T. M., Lane, N., Khan, M. A., Ehrmantraut, G., & Goodenowe, D. B. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-227 · Cited by 41
Lipids and brain inflammation in APOE4-associated dementia
Duro, M. V. V., Ebright, B., & Yassine, H. N. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000801 · Cited by 39
Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau
Kling, M. A., Goodenowe, D. B., Senanayake, V. K., MahmoudianDehkordi, S., Arnold, M., Massaro, T., Baillie, R., Han, X., Leung, Y. Y., Saykin, A. J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12110 · Cited by 37
The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease
Ehtezazi, T., Rahman, K., Davies, R., & Leach, A. G. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220071 · Cited by 37
Regioisomers of Phosphatidylcholine Containing DHA and Their Potential to Deliver DHA to the Brain: Role of Phospholipase Specificities
Chen, S., & Subbaiah, P. V. (2013) · Lipids · doi:10.1007/s11745-013-3791-5 · Cited by 35
Docosahexaenoic fatty acid (DHA) in the regulation of colon cell growth and cell death: A review
Skender, B., Vaculová, A. H., & Hofmanová, J. (2012) · Biomedical Papers · doi:10.5507/bp.2012.093 · Cited by 35
High throughput multiorgan metabolomics in the APP/PS1 mouse model of Alzheimer's disease
González‐Domínguez, R., García‐Barrera, T., Vitórica, J., & Gómez‐Ariza, J. L. (2015) · Electrophoresis · doi:10.1002/elps.201400544 · Cited by 35
The Implications for Cells of the Lipid Switches Driven by Protein–Membrane Interactions and the Development of Membrane Lipid Therapy
Torres, M., Rosselló, C. A., Fernández‐García, P., Lladó, V., Kakhlon, O., & Escribá, P. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072322 · Cited by 35
Serum cholesterol and variant in cholesterol-related gene CETP predict white matter microstructure
Warstadt, N. M., Dennis, E. L., Jahanshad, N., Omid Kohannim, A., Nir, T. M., McMahon, K. L., de Zubicaray, G. I., Montgomery, G. W., Henders, A. K., Martin, N. G., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.024 · Cited by 34
A blood‐based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial
Bowman, G. L., Dodge, H. H., Guyonnet, S., Zhou, N., Donohue, J., Bichsel, A., Schmitt, J. A. J., Hooper, C., Bartfai, T., Andrieu, S., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.004 · Cited by 35
The essential nature of dietary omega-3 fatty acids in dogs
Bauer, J. E. (2016) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.249.11.1267 · Cited by 36
Modulations of bioactive lipids and their receptors in postmortem Alzheimer’s disease brains
Kurano, M., Saito, Y., Uranbileg, B., Saigusa, D., Kano, K., Aoki, J., & Yatomi, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1066578 · Cited by 30
Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer’s Disease
Pan, Y., Omori, K., Ali, I., Tachikawa, M., Terasaki, T., Brouwer, K. L. R., & Nicolazzo, J. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00500 · Cited by 30
Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
van Wijk, N., Slot, R. E. R., Duits, F. H., Strik, M., Biesheuvel, E., Sijben, J., Blankenstein, M. A., Bierau, J., van der Flier, W. M., Scheltens, P., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.04.005 · Cited by 29
Altered protein expression of membrane transporters in isolated cerebral microvessels and brain cortex of a rat Alzheimer's disease model
Puris, E., Auriola, S. O. K., Petralla, S., Hartman, R., Gynther, M., de Lange, E. C. M., & Fricker, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105741 · Cited by 30
Healthy brain ageing and cognition: Nutritional factors
Vandewoude, M. F. J., Barberger‐Gateau, P., Cederholm, T., Mecocci, P., Salvà, A., Sergi, G., Topinková, E., & van Asselt, D. (2016) · European Geriatric Medicine · doi:10.1016/j.eurger.2015.12.005 · Cited by 31

Authors: Astarita, G., Jung, K.-M., Berchtold, N. C., Nguyen, V. Q., Gillen, D. L., Head, E., Cotman, C. W., & Piomelli, D.
Affiliations: University of Rome Tor Vergata (IT)
University of California, Irvine (US)
University of Kentucky (US)
Corresponding author: Piomelli, Daniele
ORCID: Astarita, Giuseppe
Jung, Kwang-Mook
Nguyen, Vinh Q.
Gillen, Daniel L.
Head, Elizabeth
Cotman, Carl W.
Piomelli, Daniele
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2010-09-08
Volume: 5
Issue: 9
Pages: e12538
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0012538
PMC: PMC2935886
OpenAlex: W1993630867
Cited by: 218
References: 42
Citations by year: 2026: 3 · 2025: 6 · 2024: 17 · 2023: 9 · 2022: 15 · 2021: 19 · 2020: 16 · 2019: 15 · 2018: 9 · 2017: 18 · 2016: 19 · 2015: 21 · 2014: 14 · 2013: 14 · 2012: 11
FWCI: 11.23
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
UKnowledge (University of Kentucky) (submittedVersion, cc-by)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Figshare (submittedVersion, cc-by)
Funders: Michael J. Fox Foundation for Parkinson's Research (05-901, 211002, P30 AG19610)
Agilent Foundation
Arizona Department of Health Services (P30 AG19610, P50 AG016573, 05-901, 211002, Contract 211002)
Arizona Biomedical Research Commission (P30 AG19610, 05–901, 211002)
University of California, Irvine (P50AG016573)
National Institute on Aging (211002, P01AG000538, P30-AG-19610, AG-016573, P01 AG00538, AG-19610, AG 00538, P50AG016573, P30AG019610, 05-901)
National Institute on Drug Abuse (R01DA012447)
Topics: Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: docosahexaenoic acid, Alzheimer's disease, cognitive impairment, omega-3 fatty acids, temporal cortex, cerebellum
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Docosahexaenoic Acids, Female, Humans, Liver, Male, Neuropsychological Tests, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks